Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study

Eran van Veldhuisen, Marieke S. Walma, L. Bengt van Rijssen, Olivier R. Busch, Rutger C. G. Bruijnen, Otto M. van Delden, Nadia Haj Mohammad, Ignace H. de Hingh, Lonneke S. Yo, Hanneke W. van Laarhoven, Maarten S. van Leeuwen, C. Yung Nio, Hjalmar C. van Santvoort, Jan de Vries, Frank J. Wessels, Johanna W. Wilmink, I. Quintus Molenaar, Marc G. Besselink, Krijn P. van Lienden, Dutch Pancreatic Cancer Group

Research output: Contribution to journalArticleAcademicpeer-review


Background: Determining the resectability of locally advanced pancreatic cancer (LAPC) after FOLFIRINOX chemotherapy is challenging because CT-scans cannot reliably assess vascular involvement. This study evaluates the added value of intra-operative ultrasound (IOUS) in LAPC following FOLFIRINOX induction chemotherapy. Methods: Prospective multicenter study in patients with LAPC who underwent explorative laparotomy with IOUS after FOLFIRINOX chemotherapy. Resectability was defined according to the National Comprehensive Cancer Network guidelines. IOUS findings were compared with preoperative CT-scans and pathology results. Results: CT-staging in 38 patients with LAPC after FOLFIRINOX chemotherapy defined 22 patients LAPC, 15 borderline resectable and one resectable. IOUS defined 19 patients LAPC, 13 borderline resectable and six resectable. In 12/38 patients, IOUS changed the resectability status including five patients from borderline resectable to resectable and five patients from LAPC to borderline resectable. Two patients were upstaged from borderline resectable to LAPC. Tumor diameters were significantly smaller upon IOUS (31.7 ± 9.5 mm versus 37.1 ± 10.0 mm, p = 0.001) and resectability varied significantly (p = 0.043). Ultimately, 20 patients underwent resection of whom 14 were evaluated as (borderline) resectable on CT-scan, and 17 on IOUS. Discussion: This prospective study demonstrates that IOUS may change the resectability status up to a third of patients with LAPC following FOLFIRINOX chemotherapy.
Original languageEnglish
Pages (from-to)1385-1392
Number of pages8
Issue number10
Publication statusPublished - 1 Oct 2019

Cite this